GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Burzynski Research Institute Inc (OTCPK:BZYR) » Definitions » ROA %

Burzynski Research Institute (Burzynski Research Institute) ROA % : -115,466.67% (As of Nov. 2023)


View and export this data going back to . Start your Free Trial

What is Burzynski Research Institute ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Burzynski Research Institute's annualized Net Income for the quarter that ended in Nov. 2023 was $-1.73 Mil. Burzynski Research Institute's average Total Assets over the quarter that ended in Nov. 2023 was $0.00 Mil. Therefore, Burzynski Research Institute's annualized ROA % for the quarter that ended in Nov. 2023 was -115,466.67%.

The historical rank and industry rank for Burzynski Research Institute's ROA % or its related term are showing as below:

BZYR' s ROA % Range Over the Past 10 Years
Min: -142400   Med: -23119.05   Max: -6423.53
Current: -74250

During the past 13 years, Burzynski Research Institute's highest ROA % was -6423.53%. The lowest was -142400.00%. And the median was -23119.05%.

BZYR's ROA % is ranked worse than
100% of 1553 companies
in the Biotechnology industry
Industry Median: -34.84 vs BZYR: -74250.00

Burzynski Research Institute ROA % Historical Data

The historical data trend for Burzynski Research Institute's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burzynski Research Institute ROA % Chart

Burzynski Research Institute Annual Data
Trend Feb14 Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6,423.53 -7,780.95 -11,466.67 -32,566.67 -26,171.43

Burzynski Research Institute Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -50,600.00 -43,200.00 -76,533.33 -67,200.00 -115,466.67

Competitive Comparison of Burzynski Research Institute's ROA %

For the Biotechnology subindustry, Burzynski Research Institute's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Burzynski Research Institute's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Burzynski Research Institute's ROA % distribution charts can be found below:

* The bar in red indicates where Burzynski Research Institute's ROA % falls into.



Burzynski Research Institute ROA % Calculation

Burzynski Research Institute's annualized ROA % for the fiscal year that ended in Feb. 2023 is calculated as:

ROA %=Net Income (A: Feb. 2023 )/( (Total Assets (A: Feb. 2022 )+Total Assets (A: Feb. 2023 ))/ count )
=-0.916/( (0.005+0.002)/ 2 )
=-0.916/0.0035
=-26,171.43 %

Burzynski Research Institute's annualized ROA % for the quarter that ended in Nov. 2023 is calculated as:

ROA %=Net Income (Q: Nov. 2023 )/( (Total Assets (Q: Aug. 2023 )+Total Assets (Q: Nov. 2023 ))/ count )
=-1.732/( (0.002+0.001)/ 2 )
=-1.732/0.0015
=-115,466.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Nov. 2023) net income data. ROA % is displayed in the 30-year financial page.


Burzynski Research Institute  (OTCPK:BZYR) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Nov. 2023 )
=Net Income/Total Assets
=-1.732/0.0015
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-1.732 / 0)*(0 / 0.0015)
=Net Margin %*Asset Turnover
=N/A %*0
=-115,466.67 %

Note: The Net Income data used here is four times the quarterly (Nov. 2023) net income data. The Revenue data used here is four times the quarterly (Nov. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Burzynski Research Institute ROA % Related Terms

Thank you for viewing the detailed overview of Burzynski Research Institute's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Burzynski Research Institute (Burzynski Research Institute) Business Description

Traded in Other Exchanges
N/A
Address
9432 Katy Freeway, Houston, TX, USA, 77055
Burzynski Research Institute Inc engages in the research, production, marketing, promotion, and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name Antineoplastons. Antineoplastons are used in the treatment of human cancer. Its pipeline development programs of the company include clinical trials for the treatment of a wide variety of cancers using only a combination of Antineoplastons A10 and AS2-1.
Executives
Monika Szopa-paszkowiak director 9432 KATY FWY #200, HOUSTON TX 77055
Frederick Richard Schiff director 9432 KATY FREEWAY, HOUSTON TX 77055
Barbara Burzynski director, 10 percent owner 9432 KATY FREEWAY, HOUSTON TX 77055
Carlton Hazlewood director 9432 KATY FREEWAY, HOUSTON TX 77055
Patryk Goscianski officer: Secretary and Treasurer 9432 KATY FREEWAY, HOUSTON TX 77055
Gregory Burzynski director 9432 KATY FREEWAY, HOUSTON TX 77055
Tomasz Janicki officer: VP of Clinical Trials 9432 KATY FREEWAY, HOUSTON TX 77055
Michael Driscoll director 9432 KATY FREEWAY, HOUSTON TX 77055
Stanislaw Burzynski director, 10 percent owner, officer: President 9432 KATY FREEWAY, HOUSTON TX 77055
Dudley Reece Anderson officer: Chief Financial Officer 9432 OLD KATY RD., SUITE 200, HOUSTON TX 77055

Burzynski Research Institute (Burzynski Research Institute) Headlines

No Headlines